MetaCap

Amylyx Pharmaceuticals Inc. (AMLX)

NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.02-0.18 (-0.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AMLX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.43
52-week range
10.83 – 41.14
Day range
25.52 – 26.40
Volume / Avg
1.14M / 1.53M
Beta
—

52-week range

$10.83$41.14

AMLX stock today

Amylyx Pharmaceuticals (AMLX) closed at $26.02 on Nov 20, down 0.69% (-$0.18), versus the S&P 500's 3.70% decline. At this level, AMLX sits in the middle of its 52-week range of $10.83 to $41.14: 36.8% below the high, set on Aug 21, 2026 and 140.3% above the low. AMLX is up 115.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 77.4%.

Amylyx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.43), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Amylyx Pharmaceuticals

Company profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joshua B. Cohen
Headquarters
Cambridge, MA
Employees
136
IPO year
2022
Website
amylyx.com

Financial highlights

Full financials

In fiscal 2025, Amylyx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Amylyx Pharmaceuticals reported a net loss of $144.7 million, compared with a loss of $301.7 million a year earlier. Diluted earnings per share came in at -$1.53.

Amylyx Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$87.37M$380.79M$22.23M$285.00K
Growth-100.00%-77.06%+1612.94%+7700.00%—
Net income$-144.74M$-301.74M$49.27M$-198.38M$-87.93M
EPS (diluted)$-1.53$-4.43$0.70$-3.39$-13.35

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$43.00+65.26%

  • Strong buy 0
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $25.00High $57.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.38 vs $-0.38

AMLX news

All AMLX news

Amylyx Pharmaceuticals peers

Health Care sector
AMLX peer companies
CompanyPrice% ChgMarket capCompare
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs AMLX
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs AMLX
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs AMLX
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs AMLX
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs AMLX
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs AMLX
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs AMLX
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs AMLX

Indexes, lists and sector

Amylyx Pharmaceuticals stock FAQ

What is Amylyx Pharmaceuticals's stock price today?

AMLX last traded at $26.02 as of Nov 20, 4:00 PM EST, down 0.69% on the day. Prices are delayed at least 15 minutes.

Who is Amylyx Pharmaceuticals's CEO?

Mr. Joshua B. Cohen is the chief executive officer of Amylyx Pharmaceuticals Inc., which has about 136 employees.

What is the AMLX 52-week high?

The 52-week high for AMLX is $41.14 and the 52-week low is $10.83. The stock is currently 36.8% below its high.

Compare AMLX